HRP20170770T1 - Uporaba poliola za dobivanje stabilnih polimorfnih oblika rifaksimina - Google Patents
Uporaba poliola za dobivanje stabilnih polimorfnih oblika rifaksimina Download PDFInfo
- Publication number
- HRP20170770T1 HRP20170770T1 HRP20170770TT HRP20170770T HRP20170770T1 HR P20170770 T1 HRP20170770 T1 HR P20170770T1 HR P20170770T T HRP20170770T T HR P20170770TT HR P20170770 T HRP20170770 T HR P20170770T HR P20170770 T1 HRP20170770 T1 HR P20170770T1
- Authority
- HR
- Croatia
- Prior art keywords
- rifaximin
- water content
- stabilized
- compounds according
- remaining water
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims 13
- 229960003040 rifaximin Drugs 0.000 title claims 13
- 229920005862 polyol Polymers 0.000 title claims 4
- 150000003077 polyols Chemical class 0.000 title claims 4
- 150000001875 compounds Chemical group 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 238000007605 air drying Methods 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
- C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
- C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (14)
1. Uporaba jednog ili više spojeva koji nose barem dvije hidroksi skupine otopljene u vodenoj otopini naznačena time da je za stabiliziranje polimorfnih oblika rifaksimina.
2. Uporaba kako je zatraženo u zahtjevu 1 jednog ili više spojeva koji su odabrani iz skupine koja sadrži poliole koji sadrže dva do sedam ugljikovih atoma i dvije do sedam hidroksi skupina, monosaharide, disaharide, polisaharide kao što je škrob, celuloza, i njihovi derivati, dekstrin i maltodekstrin, ksantan guma, di-hidroksi kiseline i poli-hidroksi kiseline.
3. Uporaba 1,2,3-propantriola kako je zatraženo u zahtjevu 1.
4. Uporaba kako je zatraženo u zahtjevu 2 poliola koji ima opću formulu H-[O-CH2-CH2]n-OH, pri čemu n može biti u rasponu između 2 i 14.
5. Uporaba 1,2-propandiola kako je zatraženo u zahtjevu 2.
6. Uporaba kako je zatraženo u zahtjevu 1 spoja za dobivanje rifaksimina u krutom stanju u polimorfnom obliku β koji ima preostali udio vode manji od 4.5 %.
7. Polimorfni oblici rifaksimina u krutom stanju naznačeni time da su stabilizirani uporabom jednog ili više spojeva prema zahtjevima 1 do 5, neovisno od preostalog udjela vode.
8. Rifaksimin polimorf β u krutom stanju, naznačen time da je stabiliziran uporabom jednog ili više spojeva prema zahtjevima 1 do 5, neovisno od preostalog udjela vode.
9. Oralni i topikalni medicinski preparati koji sadrže rifaksimin u polimorfnom obliku β naznačen time da je stabiliziran uporabom jednog ili više spojeva prema zahtjevima 1 do 5, neovisno od preostalog udjela vode zajedno s pomoćnim sredstvima dobro poznatim u stanju tehnike, kao što su razrjeđivači, ligandi, lubrikanti, sredstva za usitnjavanje, boje, arome i zaslađivači, za liječenje patoloških stanja koja trebaju antibiotsku terapiju.
10. Mikrogranule gastrootpornog rifaksimina β naznačene time da se polimorf β stabilizira s jednim ili više spojeva prema zahtjevima 1 do 5, neovisno od preostalog udjela vode.
11. Rifaksimin β u termo-zavarenim vrećicama naznačen time da se polimorf β stabilizira uporabom jednog ili više spojeva prema zahtjevima 1 do 5, neovisno od preostalog udjela vode.
12. Rifaksimin β u obliku tablete naznačen time da se polimorf β stabilizira uporabom jednog ili više spojeva kako je zatraženo u zahtjevima 1 do 5, neovisno od preostalog udjela vode.
13. Postupak za dobivanje rifaksimina u polimorfnom obliku β prema zahtjevu 8, naznačen time da se rifaksimin u krutom stanju dovodi u kontakt s vodenom otopinom jednog ili više spojeva prema zahtjevu 1 do 5, u koncentraciji od 5% do 59% (w/w), kod temperature između 30°C i 90°C, tijekom perioda vremena koji je između 1 i 24 sata, te time da, se nakon odvajanja preostalih krutih tvari, suši kod temperature od između 30 i 80°C, kod tlaka okoline ili pod vakuumom, tijekom perioda vremena koji je između 2 i 72 sata.
14. Postupak za dobivanje rifaksimina u polimorfnom obliku β prema zahtjevu 8, naznačen time da se vodena otopina poliola koja sadrži jedan ili više spojeva prema zahtjevima 1 do 5 u koncentracijama u opsegu od 5 do 50% (w/w) raspršuje na rifaksimin β u krutom stanju u aparatu s fluidiziranim slojem kod ulazne temperature između 40°C i 90°C i tako dobivena smjesa se podvrgava sušenju pod strujom zraka kod temperature između 40 i 90°C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001692A ITMI20061692A1 (it) | 2006-09-05 | 2006-09-05 | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
EP07804680.2A EP2059232B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
PCT/IB2007/002199 WO2008029208A1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170770T1 true HRP20170770T1 (hr) | 2017-08-11 |
Family
ID=38714944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090198A HRP20090198A9 (hr) | 2006-09-05 | 2009-04-03 | Upotreba poliola za dobivanje stabilnih oblika rifaksimina |
HRP20170770TT HRP20170770T1 (hr) | 2006-09-05 | 2017-05-23 | Uporaba poliola za dobivanje stabilnih polimorfnih oblika rifaksimina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090198A HRP20090198A9 (hr) | 2006-09-05 | 2009-04-03 | Upotreba poliola za dobivanje stabilnih oblika rifaksimina |
Country Status (34)
Country | Link |
---|---|
US (4) | US8217054B2 (hr) |
EP (2) | EP2059232B1 (hr) |
JP (1) | JP5399903B2 (hr) |
KR (2) | KR101279477B1 (hr) |
CN (1) | CN101511343B (hr) |
AR (1) | AR062383A1 (hr) |
AU (1) | AU2007293266B2 (hr) |
BR (1) | BRPI0715853B8 (hr) |
CA (1) | CA2645724C (hr) |
CY (1) | CY1119132T1 (hr) |
DK (1) | DK2059232T3 (hr) |
EA (1) | EA015002B1 (hr) |
ES (1) | ES2626236T3 (hr) |
HR (2) | HRP20090198A9 (hr) |
HU (1) | HUE034300T2 (hr) |
IL (1) | IL196800A (hr) |
IT (1) | ITMI20061692A1 (hr) |
JO (1) | JO3640B1 (hr) |
LT (1) | LT2059232T (hr) |
MA (1) | MA30726B1 (hr) |
ME (1) | ME00600B (hr) |
MX (1) | MX2009002445A (hr) |
MY (1) | MY178450A (hr) |
NO (1) | NO345200B1 (hr) |
NZ (1) | NZ574625A (hr) |
PL (1) | PL2059232T3 (hr) |
PT (1) | PT2059232T (hr) |
RS (1) | RS56024B1 (hr) |
SI (1) | SI2059232T1 (hr) |
TN (1) | TN2009000030A1 (hr) |
TW (1) | TWI335822B (hr) |
UA (1) | UA97108C2 (hr) |
WO (1) | WO2008029208A1 (hr) |
ZA (1) | ZA200900833B (hr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
US9211258B2 (en) * | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
CN103827122B (zh) | 2011-02-11 | 2016-08-31 | 萨利克斯药品有限公司 | 利福昔明的形式及其用途 |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
CA2876737A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
AU2014229467A1 (en) | 2013-03-15 | 2015-08-06 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections. |
EP2971062A2 (en) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Method for diagnosing vaginal infections |
EP2983647B1 (en) * | 2013-04-12 | 2020-09-09 | Alfasigma S.p.A. | Nsaid administration and related compositions, methods and systems |
US9474699B2 (en) * | 2014-03-31 | 2016-10-25 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of a basic benefit agent |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
JP6576953B2 (ja) | 2014-05-12 | 2019-09-18 | アルファシグマ ソシエタ ペル アチオニ | リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用 |
WO2018197538A1 (en) * | 2017-04-26 | 2018-11-01 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
KR101997341B1 (ko) * | 2017-09-05 | 2019-10-01 | 고려대학교 세종산학협력단 | 박막 트랜지스터 및 그 제조 방법 |
FR3123563A1 (fr) * | 2021-06-03 | 2022-12-09 | Algotherapeutix | Utilisation de l’amitriptyline et/ou l’un de ses sels pharmaceutiquement acceptable comme agent conservateur |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
US4462928A (en) * | 1983-03-31 | 1984-07-31 | Texaco Inc. | Partial oxidation of heavy refinery fractions |
GB8333815D0 (en) | 1983-12-20 | 1984-02-01 | Procter & Gamble | Fabric softeners |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
IT1245907B (it) | 1991-05-17 | 1994-10-25 | Alfa Wassermann Spa | Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica. |
ATE140620T1 (de) | 1991-12-05 | 1996-08-15 | Mallinckrodt Veterinary Inc | Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe |
IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20040260188A1 (en) | 2003-06-17 | 2004-12-23 | The General Hospital Corporation | Automated auscultation system |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20070281960A1 (en) | 2004-07-16 | 2007-12-06 | Amar Lulla | Anti-Histaminic Composition |
DE102005004518A1 (de) | 2005-01-31 | 2006-10-12 | Behr Gmbh & Co. Kg | Ausgleichsbehälter für ein Kühlmittel für einen Kühlkreislauf, insbesondere für einen Niedertemperaturkreislauf für indirekte Ladeluftkühlung für einen Verbrennungsmotor, Kühlkreislauf, insbesondere Niedertemperaturkreislauf für indirekte Ladeluftkühlung für einen Verbrennungsmotor, Verfahren zur Kühlung einer Heißkomponente, insbesondere eines Verbrennungsmotors |
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
JP2011500552A (ja) | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | 胃腸障害を処置するための医薬用組み合わせおよび組成物 |
PE20121185A1 (es) | 2009-10-27 | 2012-09-15 | Lupin Ltd | Dispersion solida de rifaximina |
IT1401253B1 (it) | 2010-04-23 | 2013-07-18 | Uni Degli Studi Carlo Bo Urbino | Uso del sulodexide per la riduzione delle metalloproteinasi di matrice. |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
-
2006
- 2006-09-05 IT IT001692A patent/ITMI20061692A1/it unknown
-
2007
- 2007-07-30 TW TW096127714A patent/TWI335822B/zh active
- 2007-07-31 US US12/439,094 patent/US8217054B2/en active Active
- 2007-07-31 PT PT78046802T patent/PT2059232T/pt unknown
- 2007-07-31 MY MYPI20090549A patent/MY178450A/en unknown
- 2007-07-31 NZ NZ574625A patent/NZ574625A/en unknown
- 2007-07-31 KR KR1020097004604A patent/KR101279477B1/ko active IP Right Grant
- 2007-07-31 BR BRPI0715853A patent/BRPI0715853B8/pt active IP Right Grant
- 2007-07-31 ME MEP-2009-81A patent/ME00600B/me unknown
- 2007-07-31 WO PCT/IB2007/002199 patent/WO2008029208A1/en active Application Filing
- 2007-07-31 EA EA200900282A patent/EA015002B1/ru unknown
- 2007-07-31 RS RS20170520A patent/RS56024B1/sr unknown
- 2007-07-31 ZA ZA200900833A patent/ZA200900833B/xx unknown
- 2007-07-31 KR KR1020127001116A patent/KR101359327B1/ko active IP Right Grant
- 2007-07-31 LT LTEP07804680.2T patent/LT2059232T/lt unknown
- 2007-07-31 EP EP07804680.2A patent/EP2059232B1/en active Active
- 2007-07-31 UA UAA200811412A patent/UA97108C2/uk unknown
- 2007-07-31 HU HUE07804680A patent/HUE034300T2/en unknown
- 2007-07-31 EP EP17157159.9A patent/EP3187174A1/en not_active Withdrawn
- 2007-07-31 PL PL07804680T patent/PL2059232T3/pl unknown
- 2007-07-31 SI SI200731941A patent/SI2059232T1/sl unknown
- 2007-07-31 AU AU2007293266A patent/AU2007293266B2/en active Active
- 2007-07-31 JP JP2009526185A patent/JP5399903B2/ja active Active
- 2007-07-31 CN CN2007800330052A patent/CN101511343B/zh active Active
- 2007-07-31 DK DK07804680.2T patent/DK2059232T3/en active
- 2007-07-31 ES ES07804680.2T patent/ES2626236T3/es active Active
- 2007-07-31 MX MX2009002445A patent/MX2009002445A/es active IP Right Grant
- 2007-07-31 CA CA2645724A patent/CA2645724C/en active Active
- 2007-08-15 AR ARP070103627A patent/AR062383A1/es not_active Application Discontinuation
- 2007-09-05 JO JOP/2007/0373A patent/JO3640B1/ar active
-
2008
- 2008-09-19 NO NO20083988A patent/NO345200B1/no unknown
-
2009
- 2009-01-28 TN TN2009000030A patent/TN2009000030A1/fr unknown
- 2009-01-29 IL IL196800A patent/IL196800A/en active IP Right Grant
- 2009-03-30 MA MA31743A patent/MA30726B1/fr unknown
- 2009-04-03 HR HR20090198A patent/HRP20090198A9/hr not_active Application Discontinuation
-
2012
- 2012-07-09 US US13/544,945 patent/US8748449B2/en active Active
-
2014
- 2014-04-28 US US14/263,845 patent/US20150072002A1/en not_active Abandoned
-
2016
- 2016-05-12 US US15/153,636 patent/US10280177B2/en active Active
-
2017
- 2017-05-23 HR HRP20170770TT patent/HRP20170770T1/hr unknown
- 2017-05-26 CY CY20171100546T patent/CY1119132T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170770T1 (hr) | Uporaba poliola za dobivanje stabilnih polimorfnih oblika rifaksimina | |
FI64796B (fi) | Foerfarande foer resolvering av (+)-6-metoxi-alfa-metyl-2-naftalensyra som fri syra eller n-metyl-d-glukaminsalt ur en blandning och i foerfarande anvaent resolveringsmedium | |
CN103833692B (zh) | 一种从海藻中提取高纯度岩藻黄素的方法 | |
US7425578B2 (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
JP2010502584A5 (hr) | ||
CN107098879B (zh) | 一种具有抗菌活性的异黄酮类化合物及其制备方法与应用 | |
CN101691349B (zh) | 一种从发酵液中提取色氨酸的工艺 | |
CN101704811B (zh) | 一种高纯度的雷贝拉唑钠化合物 | |
AU2001285311A1 (en) | Immunoregulatory compounds, derivatives thereof and their use | |
WO2012057596A1 (es) | Mezcla y método por hplc para la cuantificación de astaxantina en residuos de camarón fermentados | |
JPWO2019065396A1 (ja) | 精製サラシア属植物抽出物の製造方法および精製サラシア属植物抽出物 | |
CN104860832B (zh) | 一种治疗呼吸系统疾病的药物盐酸氨溴索组合物 | |
KR101592251B1 (ko) | 갈조류로부터 플로로탄닌 정제물의 제조방법 | |
CN101628903B (zh) | 具有免疫作用的退热、抗炎、抗感染药物及其制备和用途 | |
JP5032461B2 (ja) | 水中でのチオクト酸の精製方法 | |
CN101279979A (zh) | 头孢孟多酯钠的分离纯化方法及冻干粉针制剂的制备方法 | |
CN110143957B (zh) | 头孢妥仑匹酯开环物的制备方法 | |
CN112391436A (zh) | 一种富含nmn毛豆肽及其制备方法和应用 | |
JP2010150209A5 (hr) | ||
WO2016010093A1 (ja) | 非晶質クルクミン及び/又はその類縁体を含有する複合体の製造方法 | |
JP6428527B2 (ja) | ピロロキノリンキノン結晶の製造方法 | |
WO2007083631A1 (ja) | S-アデノシル-l-メチオニンの安定化法及び安定化された組成物 | |
WO2007004238A3 (en) | A process for the manufacture of divalproex sodium | |
CN105367421B (zh) | 荚蒾乙素、其制备方法及用途 | |
CN102617327A (zh) | 右旋布洛芬化合物及其制法 |